Journal of Xenobiotics, Год журнала: 2025, Номер 15(2), С. 51 - 51
Опубликована: Март 31, 2025
Cardiovascular diseases (CVDs) represent a leading cause of premature mortality and disability worldwide, with their incidence expected to rise, potentially reaching 24 million deaths per year by 2030. These multifactorial diseases, including hypertension, coronary artery disease, arrhythmia, heart failure, are often linked metabolic disturbances such as diabetes, oxidative stress, endothelial dysfunction, inflammation. Natural compounds, caffeine, have been explored for potential therapeutic effects on CVDs. Caffeine, found in coffee, tea, cocoa, various energy drinks, is widely consumed psychoactive compound noted analgesic anti-inflammatory properties. Despite its long history use, caffeine’s impact cardiovascular health remains controversial, both beneficial harmful reported. This review examines the current literature caffeine (CVDs), an emphasis preclinical clinical studies, pharmacokinetic properties, molecular mechanisms it modulates. There evidence that moderate intake can be some CVDs, while other dyslipidemia, collected so far suggests could detrimental since increases total cholesterol levels. But variability dosage, patterns, individual factors (such genetics diet) complicates reliability results. Additionally, challenges related dose standardization absence consistent trial designs hinder full utilization CVD treatment. Nonetheless, appears safe individuals without significant conditions. Future research should aim well-designed studies precise patient cohorts standardized methodologies better assess role management.
Язык: Английский